In the current study, we found strong and relatively homogeneous TROP2 expression in the membrane in sebaceous carcinoma and sweat gland carcinoma, which directly suggests that the tumors are potential targets of TROP2-targeted ADCs (e.g., sacituzumab govitecan). Here, TACSTD2 is linked to sweat gland carcinoma.